Clinical Trial Update: Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating the safety and efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurotrophic Keratitis

Drugs mentioned

• CSB-001 Ophthalmic Solution 0.1% (CSB-001)

Snippet

Sponsor: Claris Biotherapeutics, Inc. | Conditions: Neurotrophic Keratitis | Phase 1, Phase 2 | Status: COMPLETED